Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures

Trial Profile

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Myocardial infarction; Peripheral arterial disorders; Peripheral ischaemia; Stroke; Thrombosis; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VOYAGER PAD
  • Sponsors Bayer; Bayer HealthCare; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
  • Most Recent Events

    • 14 Nov 2023 According to Janssen media release, results from this trial were presented at the American Heart Association's (AHA) 2023 Scientific Sessions.
    • 14 Nov 2023 Results assessing the role of XARELTO in treating both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD) presented in the Janssen Media Release.
    • 13 Nov 2023 Results analyzing impact of low dose Rivaroxaban Plus Aspirin on myocardial infarction in patients with peripheral artery disease with and without concomitant coronary artery disease, presented at the American Heart Association Scientific Sessions 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top